Fig. 2. Flt3L/αCD40 therapy induces regression of KPneo tumors and has a mild impact on KPctrl tumors.
A Scheme of anti-PD-L1 (αPD-L1) or IgG treatment in KPctrl or KPneo tumors (left). Tumor outgrowth (right). B Flt3L and anti-CD40 (FL/αCD40) therapy or IgG administration scheme in KPctrl and KPneo tumors (left). Tumor outgrowth (right). C Growth of individual tumors showed in (B), indicating the fraction of rejected tumors in each group. D Frequencies of effector/effector memory (CD44+/CD62L-) CD8 T cells in the tdLN at day 12 after tumor challenge. E Frequencies (left) and absolute numbers (right) of tumor-infiltrating CD8 T cells at day 12. F Percentage (left) and absolute numbers (right) of tumor-infiltrating CD8 T cells at the endpoint (day 21). G Tumor CD8/Treg ratio at day 21. A–G Data from one out of two independent experiments is presented (n = 6 mice per group, per experiment). H, I IFN-γ ELISpot showing the specificities of CD8 T cells under FL/αCD40 therapy, induced by KPctrl tumors and tested for shared peptides (H) or by KPneo tumors and tested for unique neoAgs (I). n = 3, data represent spots from pooled CD8 T cells from 3 mice per group, one out of three independent experiments. Two-way ANOVA followed by Tukey’s post-test in A-G; two-tailed Multiple t-test with Holm-Sidak correction method in (H, I). All data are plotted as mean ± SEM. Source data are provided as a Source Data File.